Literature DB >> 22449504

Multidisciplinary treatment approach in Treacher Collins syndrome.

Joseph B Hylton1, Vladimir Leon-Salazar, Gary C Anderson, Nanci L O De Felippe.   

Abstract

Treacher Collins syndrome (TCS) is a common genetic disorder with high penetrance and phenotypic variability. First and second branchial arches are affected in TCS, resulting in craniofacial and intraoral anomalies such as: severe convex facial profile; mid-face hypoplasia; microtia; eyelid colobomas; mandibular retrognathism; cleft palate; dental hypoplasia; heterotopic teeth; maxillary transverse hypoplasia; anterior open bite; and Angle Class II molar relationship. A high incidence of caries is also a typical finding in TCS patients. Nonetheless, even simple dental restorative procedures can be challenging in this patient population due to other associated medical conditions, such as: congenital heart defects; decreased oropharyngeal airways; hearing loss; and anxiety toward treatment. These patients often require a multidisciplinary treatment approach, including: audiology; speech and language pathology; otorhinolaryngology; general dentistry; orthodontics; oral and maxillofacial surgery; and plastic and reconstructive surgeries to improve facial appearance. This paper's purpose was to present a current understanding of Treacher Collins syndrome etiology, phenotype, and current treatment approaches.

Entities:  

Mesh:

Year:  2012        PMID: 22449504

Source DB:  PubMed          Journal:  J Dent Child (Chic)        ISSN: 1551-8949


  2 in total

1.  The 50 Most Cited Papers in Craniofacial Anomalies and Craniofacial Surgery.

Authors:  Nicola A Mahon; Cormac W Joyce; Sangeetha Thomas; Elizabeth Concannon; Dylan Murray
Journal:  Arch Plast Surg       Date:  2015-09-15

2.  Craniofacial Anomaly Association with the Internal Malformations in the Pediatric Age Group in Al-Fallujah City-Iraq.

Authors:  Thaer M Farhan; Basim A Al-Abdely; Abdulrahman N Abdullateef; Abdulhameed S Jubair
Journal:  Biomed Res Int       Date:  2020-08-18       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.